ACLX Stock Risk & Deep Value Analysis
Arcellx Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ACLX Stock
We analyzed Arcellx Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ACLX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
ACLX Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is the acquisition failing to close, which could happen if the tender offer conditions (like majority tender) are not met or if foreign regulatory approvals are unexpectedly denied. This would likely cause ACLX shares to drop significantly from the tender offer price, unwinding the merger arbitrage spread and exposing investors to the inherent risks of a standalone biotech.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Low
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
Shareholder lawsuits alleging disclosure deficiencies related to the acquisition.
- ⚠
Only ~7.5% of shares tendered as of March 31, 2026 (though typical for tender offers before final deadline).
Upcoming Risk Events
- 📅
Gilead tender offer fails to meet conditions (e.g., majority tender)
- 📅
Shareholder lawsuits delay or complicate acquisition closure
- 📅
Foreign regulatory bodies block the acquisition
- 📅
Anito-cel commercialization underperforms, impacting CVR payout
When to Reconsider
- 🚪
Gilead announces termination or failure of the tender offer.
- 🚪
ACLX stock price drops below $110, indicating market skepticism about deal closure.
- 🚪
Significant delays in regulatory approvals or shareholder lawsuit outcomes.
Unlock ACLX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Arcellx Inc (ACLX) Do?
Market Cap
$6.71B
Sector
Healthcare
Industry
Biotechnology
Employees
163
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Visit Arcellx Inc WebsiteInvestment Thesis
The investment thesis for ACLX is now a merger arbitrage play, betting on the successful closure of Gilead's tender offer for $115 cash per share plus a potential $5 CVR. The primary upside comes from the small spread between the current market price and the cash offer, and the long-term potential of the CVR. The company's prior growth story has been realized via acquisition.
Is ACLX Stock Undervalued?
Unlock the full AI analysis for ACLX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ACLX Price Targets & Strategy
12-Month Target
$120.00
Bull Case
$120.00
Bear Case
$100.00
Valuation Basis
Target based on Gilead's tender offer of $115 cash + $5 CVR = $120 total potential
Entry Strategy
The stock is currently trading very close to the cash tender offer price ($114.89 vs $115.00). Any entry should be seen as a merger arbitrage play, aiming to capture the small spread and potential CVR. Entry below $114.89 would be ideal to maximize the spread.
Exit Strategy
Exit upon deal close (receiving $115 cash per share) or if the stock price rises significantly above the tender offer, signaling potential issues with the CVR or a higher offer (unlikely at this stage). A stop loss below $110.00 would be prudent if the deal faces unexpected hurdles.
Portfolio Allocation
1-3% for moderate risk tolerance (as a merger arbitrage play, not a growth investment).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does ACLX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
Arcellx's intellectual property and clinical lead in anito-cel provided a competitive advantage, especially with the ddCAR platform's potential for next-generation cell therapies. This moat is durable within the specific CAR-T space, but its independent durability is now transferred to Gilead.
Moat Erosion Risks
- •Intense competition in the CAR-T space and multiple myeloma treatments (e.g., from TPST, CRSP, and other existing therapies).
- •Future regulatory hurdles for subsequent ddCAR assets.
- •Erosion of IP through new discoveries or patent challenges.
ACLX Competitive Moat Analysis
Sign up to see competitive advantages
ACLX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Focus is likely on the acquisition closing and CVR terms. Some discussion around the shareholder lawsuits and potential for delay.
Institutional Sentiment
Positive - Institutional holders who tendered would benefit from the acquisition. Vanguard reports 0% ownership post-realignment on 01/12/2026, filed 03/26/2026, indicating some realignment prior to the tender. No recent Form 4 filings reported for insider activity.
Insider Activity (Form 4)
No Form 4 filings reported for insider activity in the last 90 days. Vanguard reported 0% ownership post-realignment on 01/12/2026, filed 03/26/2026.
Options Flow
Normal options activity - likely reflecting the high probability of the deal closing, with limited volatility expected beyond the merger spread.
Earnings Intelligence
Next Earnings
No data available in results.
Surprise Probability
Low - as the company is being acquired, standalone financial performance is less relevant.
Historical Earnings Pattern
Not applicable due to pending acquisition; historical patterns would be overridden by deal dynamics.
Key Metrics to Watch
Competitive Position
Top Competitor
Kite Pharma (now part of Gilead)
Market Share Trend
Not applicable; its future market share will be part of Gilead's portfolio.
Valuation vs Peers
Not applicable as the company is being acquired at a set valuation. Its valuation as a standalone entity is no longer relevant for investment purposes.
Competitive Advantages
- •Proprietary ddCAR platform
- •Advanced CAR-T asset (anito-cel) for multiple myeloma
- •Strong development and commercialization partnership with Gilead (now acquiring)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ACLX Stock Higher?
Near-Term (0-6 months)
- •Gilead tender offer extension expiration (Apr 24, 2026)
- •Completion of acquisition by Gilead (expected Q2 2026)
- •Resolution of shareholder lawsuits (expected ~Apr 2026, disclosed in SC 14D-9/A)
Medium-Term (6-18 months)
- •Foreign regulatory approvals for acquisition (ACCC, Austrian authorities)
- •FDA approval for anito-cel (expected Q3 2026, post-acquisition)
Long-Term (18+ months)
- •Anito-cel cumulative worldwide sales exceeding $6.0B by Dec 31, 2029 (for CVR payment)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ACLX?
- ✓
Updates on the tender offer acceptance rate and conditions satisfaction.
- ✓
News regarding foreign regulatory approvals for the acquisition.
- ✓
Resolution or dismissal of the shareholder lawsuits related to the acquisition terms.
Bull Case Analysis
See what could go right with Premium
Competing with ACLX
See how Arcellx Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Arcellx Inc ACLX | $6.7B | 1.5 | — | $22.3M | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Arcellx Inc Makes Money
Prior to the acquisition, Arcellx Inc. was a clinical-stage biotechnology company focused on developing novel cell therapies for cancer and other difficult-to-treat diseases. Its primary value proposition centered on its proprietary ddCAR (D-Domain CAR) platform, designed to create more effective and safer CAR T-cell therapies. The company was in the process of advancing its lead product candidate, anito-cel (CART-ddBCMA), for patients with relapsed/refractory multiple myeloma, through clinical trials towards potential FDA approval and commercialization via a strategic partnership with Gilead Sciences. Its business model relied on successful R&D, clinical development, regulatory approval, and eventual commercial sales or lucrative partnerships and licensing agreements for its innovative therapies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Arcellx Inc (ACLX)?
As of April 6, 2026, Arcellx Inc has a DVR Score of 1.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Arcellx Inc?
Arcellx Inc's market capitalization is approximately $6.7B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Arcellx Inc use?
ACLX is the ticker symbol for Arcellx Inc. The company trades on the NMS.
What is the risk level for ACLX stock?
Our analysis rates Arcellx Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Arcellx Inc's revenue growing?
Arcellx Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ACLX stock profitable?
Arcellx Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ACLX DVR analysis updated?
Our AI-powered analysis of Arcellx Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ACLX (Arcellx Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.